

Alan J. Lewis, Ph.D. Board Member

President and CEO, Diavacs

Dr. Alan J. Lewis is the President, CEO and board member of DiaVacs, a Type 1 diabetes company. DiaVacs is developing products to reverse the onset of autoimmune diseases by reinducing tolerance into the patient's immune system.

Dr. Lewis currently serves as Chairman of the Board of Batu Biologics, a private biotechnology company, and director of a private biotechnology company, Targazyme, Inc. Dr. Lewis is a pharma industry veteran and a successful serial entrepreneur. He has served as Chief Executive Officer and Director of Medistem, Inc., Ambit Biosciences, and Novocell Inc., From January 2009 to June 2010, Dr. Lewis served as President and Chief Executive Officer of The Juvenile Diabetes Research Foundation. Prior to joining Novocell Inc., a company focused on stem cell therapy, starting in 2000, he was President of Celgene Signal Research, a wholly owned subsidiary of the Celgene Corporation, a pharmaceutical company.

From February 1994 to August 2000, he was the President and Chief Executive Officer of Signal Pharmaceuticals, Inc., where he guided the company to its successful acquisition by Celgene Corporation. From 1979 to 1994, Dr. Lewis held a number of positions at Wyeth-Ayerst Research and its predecessor, Wyeth Laboratories, Inc., including Vice President of Research at Wyeth-Ayerst Research. Dr. Lewis has published over 120 full manuscripts and has written and edited seven books. Dr. Lewis was a Research Associate at Yale University from 1972 to 1973. Dr. Lewis received a B.Sc. in physiology and biochemistry from Southampton University, Southampton, Hampshire, United Kingdom, and a Ph.D. in pharmacology from the University of Wales, Cardiff, United Kingdom.